
|Videos|April 18, 2011
Dr. Gomella on Novel Prostate Cancer Immunotherapies
Author(s)Leonard G. Gomella, MD
Dr. Leonard Gomella from the Jefferson Kimmel Cancer Center on Novel Prostate Cancer Immunotherapies
Advertisement
Leonard G. Gomella, MD, chair, Department of Urology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses novel immunotherapies that are available for prostate cancer. The most exciting immunotherapy currently approved for prostate cancer is Provenge because of its very unique nature. Gomella believes that other immunotherapies, such as ipilimumab, may also move into the prostate cancer field.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5



































